Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to $17.3 million.

  • Compass Therapeutics' Cash from Financing Activities rose 6468150.00% to $129.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $128.4 million, marking a year-over-year increase of 643.60%. This contributed to the annual value of $17.3 million for FY2024, which is 490.73% up from last year.
  • Per Compass Therapeutics' latest filing, its Cash from Financing Activities stood at $17.3 million for FY2024, which was up 490.73% from $2.9 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Cash from Financing Activities ranged from a high of $118.6 million in FY2021 and a low of $30,985 during FY2020.
  • Its 3-year average for Cash from Financing Activities is $32.0 million, with a median of $17.3 million in 2024.
  • As far as peak fluctuations go, Compass Therapeutics' Cash from Financing Activities slumped by 96.13% in 2023, and later soared by 490.73% in 2024.
  • Yearly analysis of 5 years shows Compass Therapeutics' Cash from Financing Activities stood at $30,985 in 2020, then reached $48.5 million in 2020, then surged by 144.37% to $118.6 million in 2021, then tumbled by 36.13% to $75.8 million in 2022, then slumped by 96.13% to $2.9 million in 2023, then spiked by 490.73% to $17.3 million in 2024.